Phase I Study of Single-Agent AZD1775 (MK-1775), a Wee1 Kinase Inhibitor, in Patients With Refractory Solid Tumors

MLA

Jennifer Zlott, et al. “Phase I Study of Single-Agent AZD1775 (MK-1775), a Wee1 Kinase Inhibitor, in Patients With Refractory Solid Tumors.” Journal of Clinical Oncology, vol. 33, Oct. 2015, pp. 3409–15. EBSCOhost, https://doi.org/10.1200/jco.2014.60.4009.

APA

Jennifer Zlott, Tomoko Freshwater, Khanh T. Do, Jerry M. Collins, Deborah Wilsker, Jiuping Ji, S. Kummar, James H. Doroshow, Robert J. Kinders, & Alice P. Chen. (2015). Phase I Study of Single-Agent AZD1775 (MK-1775), a Wee1 Kinase Inhibitor, in Patients With Refractory Solid Tumors. Journal of Clinical Oncology, 33, 3409–3415. https://doi.org/10.1200/jco.2014.60.4009

Chicago

Jennifer Zlott, Tomoko Freshwater, Khanh T. Do, Jerry M. Collins, Deborah Wilsker, Jiuping Ji, S. Kummar, James H. Doroshow, Robert J. Kinders, and Alice P. Chen. 2015. “Phase I Study of Single-Agent AZD1775 (MK-1775), a Wee1 Kinase Inhibitor, in Patients With Refractory Solid Tumors.” Journal of Clinical Oncology 33 (October): 3409–15. doi:10.1200/jco.2014.60.4009.